orforglipron vs Semaglutide (Rybelsus)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

orforglipron · Foundayo

Marketed by Eli Lilly and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05803421 · Phase 3 · completed

ACHIEVE-4 was a randomized, open-label, event-driven Phase 3 trial. It assigned 2,749 adults with type 2 diabetes, obesity or overweight and established cardiovascular or chronic kidney disease to oral orforglipron or injected insulin glargine once daily. The primary endpoint was time to the first major cardiovascular event, and orforglipron had to be shown non-inferior to insulin glargine, with the upper limit of the 95% confidence interval for the hazard ratio below 1.8. Over a median of 2 years, events occurred in 4.2% of orforglipron patients and 5.0% of insulin glargine patients (hazard ratio 0.84, 95% CI 0.59 to 1.20), so non-inferiority was shown and the trial met its primary endpoint. The figures come from the peer-reviewed paper in The Lancet.

Next expected readout: May 2027 · NCT07613307 (registry estimate)

Reported efficacy

Mean Percent Change from Baseline in Body Weight (Baseline, Week 72): Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001) (met)

Result source: NCT05872620

Semaglutide (Rybelsus)

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT06050577 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointorforglipronSemaglutide (Rybelsus)
HbA1c, change-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082
Body weight, change (kg)-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082
HbA1c below 7%79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
—Not posted · NCT07271251
Fasting plasma glucose, change-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080
3-point MACE (% with event)—Not posted · NCT0580342112% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result

HbA1c, change

orforglipron
-1.4% vs -0.1%−1.3 vs placebo36 mg · wk 40 · n 141NCT05971940
14 other results
  • -1.6% vs -0.1% 12 mg · wk 40 · n 137 · Phase 3 · primary NCT05971940
  • -1.3% vs -0.1% 3 mg · wk 40 · n 143 · Phase 3 · primary NCT05971940
  • -2.0% vs -0.4% 36 mg · wk 26 · n 57 · Phase 2 · primary NCT05048719
  • -1.9% vs -0.4% 12 mg · wk 26 · n 49 · Phase 2 · primary NCT05048719
  • -1.2% vs -0.4% 3 mg · wk 26 · n 46 · Phase 2 · primary NCT05048719
  • -2.1% vs -0.4% 45 mg · wk 26 · n 58 · Phase 2 · primary NCT05048719
  • -1.8% vs -0.4% 24 mg · wk 26 · n 42 · Phase 2 · primary NCT05048719
  • -2.0% vs -1.1% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -1.9% vs -1.1% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • -1.2% vs -1.1% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • -2.1% vs -1.1% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • -1.8% vs -1.1% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
  • -1.7% vs -0.5% orforglipron 17.2 mg · wk 72 · Phase 3 · primary NCT05872620
  • 1.7% vs 0.8% wk 40 · Phase 3 · primary NCT06192108
Semaglutide (Rybelsus)
-1.6% vs -0.2%−1.4 vs placebo14 mg · wk 26 · n 116NCT04109547
34 other results
  • -1.5% vs -0.2% 7 mg · wk 26 · n 117 · Phase 3 · primary NCT04109547
  • -1.1% vs -0.2% 3 mg · wk 26 · n 114 · Phase 3 · primary NCT04109547
  • -0.7% vs -0.1% wk 104 · n 4076 · Phase 3 · secondary NCT03914326
  • -1% vs -0.3% n 1489 · Phase 3 · secondary NCT02692716
  • -1.2% vs -0.1% 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -1.2% vs -0.2% 14 mg · wk 52 · n 168 · Phase 3 · secondary NCT03021187
  • -0.9% vs -0.2% 7 mg · wk 52 · n 169 · Phase 3 · secondary NCT03021187
  • -0.6% vs -0.2% 3 mg · wk 52 · n 173 · Phase 3 · secondary NCT03021187
  • -1.5% vs 0.1% 14 mg · wk 52 · n 41 · Phase 3 · secondary NCT03018028
  • -1.4% vs 0.1% 7 mg · wk 52 · n 43 · Phase 3 · secondary NCT03018028
  • -1% vs 0.1% 3 mg · wk 52 · n 38 · Phase 3 · secondary NCT03018028
  • -2% vs -1.6% 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.9% 14 mg · wk 52 · n 384 · Phase 3 · secondary NCT02863328
  • -1.2% vs -0.7% 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.1% vs -0.7% 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1% vs -0.7% 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -0.9% vs -0.7% 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.6% vs -0.7% 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8% vs -1.4% 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7% vs -1.6% 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4% vs -1.4% 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.1% vs -1.6% 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.8% vs -1.4% 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.3% vs -0.8% wk 52 · n 230 · Phase 3 · secondary NCT02849080
  • -0.2% vs 0% wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.0% vs -0.4% 40 mg · wk 26 · n 46 · Phase 2 · primary NCT01923181
  • -1.8% vs -0.4% 40 mg · wk 26 · n 52 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 40 mg · wk 26 · n 44 · Phase 2 · primary NCT01923181
  • -1.7% vs -0.4% 20 mg · wk 26 · n 48 · Phase 2 · primary NCT01923181
  • -1.6% vs -0.4% 10 mg · wk 26 · n 57 · Phase 2 · primary NCT01923181
  • -1.2% vs -0.4% 5 mg · wk 26 · n 58 · Phase 2 · primary NCT01923181
  • -0.9% vs -0.4% 2.5 mg · wk 26 · n 56 · Phase 2 · primary NCT01923181
  • -1.2% vs -1.0% wk 52 · n 326 · Phase 4 · primary NCT05035082

Body weight, change (kg)

orforglipron
-7.3 vs -1.3−6 vs placebo36 mg · wk 40 · n 141NCT05971940
7 other results
  • -5.5 vs -1.3 12 mg · wk 40 · n 137 · Phase 3 · secondary NCT05971940
  • -4.4 vs -1.3 3 mg · wk 40 · n 143 · Phase 3 · secondary NCT05971940
  • -9.5 vs -2.2 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • -6.5 vs -2.2 12 mg · wk 26 · n 53 · Phase 2 · secondary NCT05048719
  • -3.7 vs -2.2 3 mg · wk 26 · n 50 · Phase 2 · secondary NCT05048719
  • -10.1 vs -2.2 45 mg · wk 26 · n 62 · Phase 2 · secondary NCT05048719
  • -9.7 vs -2.2 24 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
Semaglutide (Rybelsus)
-4.2 vs -1.3−2.9 vs placebowk 104 · n 4251NCT03914326
39 other results
  • -4.2 vs -0.8 n 1510 · Phase 3 · secondary NCT02692716
  • -3.1 vs -1.1 14 mg · wk 26 · n 116 · Phase 3 · secondary NCT04109547
  • -4.4 vs -1 14 mg · wk 52 · n 275 · Phase 3 · secondary NCT02863419
  • -3.8 vs 0.5 14 mg · wk 52 · n 170 · Phase 3 · secondary NCT03021187
  • -2.4 vs -1.1 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -2.9 vs -1 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.2 vs -1.1 7 mg · wk 26 · n 119 · Phase 3 · secondary NCT04109547
  • -2.2 vs 0.5 7 mg · wk 52 · n 171 · Phase 3 · secondary NCT03021187
  • -1.1 vs -1.1 3 mg · wk 26 · n 115 · Phase 3 · secondary NCT04109547
  • -0.9 vs 0.5 3 mg · wk 52 · n 174 · Phase 3 · secondary NCT03021187
  • -1.2 vs -1.1 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -0.8 vs -1 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -0.4 vs -1.1 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • 0 vs -1 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -3.8 vs -0.5 14 mg · wk 26 · n 300 · Phase 3 · secondary NCT04017832
  • -4 vs -3.7 14 mg · wk 52 · n 386 · Phase 3 · secondary NCT02863328
  • -3.5 vs -0.7 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -3.2 vs -1 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.9 vs -0.5 7 mg · wk 26 · n 319 · Phase 3 · secondary NCT04017832
  • -2.5 vs -0.7 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.8 vs -1 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.2 vs 0.3 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.7 vs 1 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -0.9 vs 1 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -1.4 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.6 vs -0.7 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -1.8 vs -1 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1 vs 0.3 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.1 vs 0.3 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • 0 vs 1 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -2.6 vs -0.9 wk 104 · n 93 · Phase 3 · secondary NCT02849080
  • -6.9 vs -1.2 40 mg · wk 26 · n 46 · Phase 2 · secondary NCT01923181
  • -5.9 vs -1.2 40 mg · wk 26 · n 51 · Phase 2 · secondary NCT01923181
  • -8.3 vs -1.2 40 mg · wk 26 · n 44 · Phase 2 · secondary NCT01923181
  • -5.8 vs -1.2 20 mg · wk 26 · n 47 · Phase 2 · secondary NCT01923181
  • -4.9 vs -1.2 10 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.9 vs -1.2 5 mg · wk 26 · n 57 · Phase 2 · secondary NCT01923181
  • -2.0 vs -1.2 2.5 mg · wk 26 · n 56 · Phase 2 · secondary NCT01923181
  • -3.9 vs -3.5 wk 52 · n 290 · Phase 4 · secondary NCT05035082

HbA1c below 7%

orforglipron
79.0% vs 37.1%+41.9 vs placebo36 mg · wk 40 · n 119NCT05971940
7 other results
  • 81.3% vs 37.1% 12 mg · wk 40 · n 112 · Phase 3 · secondary NCT05971940
  • 78.2% vs 37.1% 3 mg · wk 40 · n 119 · Phase 3 · secondary NCT05971940
  • 92.8% vs 24.3% 36 mg · wk 26 · n 57 · Phase 2 · secondary NCT05048719
  • 78.9% vs 24.3% 12 mg · wk 26 · n 49 · Phase 2 · secondary NCT05048719
  • 65.2% vs 24.3% 3 mg · wk 26 · n 46 · Phase 2 · secondary NCT05048719
  • 95.8% vs 24.3% 45 mg · wk 26 · n 58 · Phase 2 · secondary NCT05048719
  • 91.2% vs 24.3% 24 mg · wk 26 · n 42 · Phase 2 · secondary NCT05048719
Semaglutide (Rybelsus)
—Not posted · NCT07271251

Fasting plasma glucose, change

orforglipron
-2.0 vs -1.1−0.9 vs placebo3/6/12/21 mg QD · wk 12 · n 7NCT04426474
4 other results
  • -3 vs -1.1 3/6/9 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.9 vs -1.1 3/6/12/15 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
  • -2.4 vs -1.1 3/6/12/21/27 mg QD · wk 12 · n 8 · Phase 1 · secondary NCT04426474
  • -2.3 vs -1.1 3/6/9/21/36/45 mg QD · wk 12 · n 9 · Phase 1 · secondary NCT04426474
Semaglutide (Rybelsus)
-1.9 vs -0.7−1.2 vs placebo14 mg · wk 52 · n 285NCT02863419
39 other results
  • -1.6 vs -0.1 14 mg · wk 52 · n 181 · Phase 3 · secondary NCT03021187
  • -1.9 vs -0.2 14 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -2.0 vs -0.3 14 mg · wk 26 · n 285 · Phase 3 · secondary NCT02863419
  • -1.6 vs -0.3 14 mg · wk 26 · n 151 · Phase 3 · secondary NCT02827708
  • -1.4 vs 0.5 14 mg · wk 26 · n 181 · Phase 3 · secondary NCT03021187
  • -1.1 vs -0.1 7 mg · wk 52 · n 182 · Phase 3 · secondary NCT03021187
  • -1.5 vs -0.2 7 mg · wk 26 · n 160 · Phase 3 · secondary NCT02906930
  • -1.1 vs 0.5 7 mg · wk 26 · n 182 · Phase 3 · secondary NCT03021187
  • -0.8 vs -0.1 3 mg · wk 52 · n 184 · Phase 3 · secondary NCT03021187
  • -0.9 vs -0.2 3 mg · wk 26 · n 166 · Phase 3 · secondary NCT02906930
  • -0.5 vs 0.5 3 mg · wk 26 · n 184 · Phase 3 · secondary NCT03021187
  • -2.3 vs 0.3 14 mg · wk 52 · n 48 · Phase 3 · secondary NCT03018028
  • -2.4 vs -0.4 14 mg · wk 26 · n 48 · Phase 3 · secondary NCT03018028
  • -1.6 vs 0.3 7 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 7 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.1 vs 0.3 3 mg · wk 52 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.4 3 mg · wk 26 · n 49 · Phase 3 · secondary NCT03018028
  • -1.6 vs -0.9 14 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 52 · n 411 · Phase 3 · secondary NCT02863328
  • -1.8 vs -1.0 14 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -2.0 vs -2.1 14 mg · wk 26 · n 411 · Phase 3 · secondary NCT02863328
  • -1.7 vs -0.9 14 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2 vs -0.5 14 mg · wk 26 · n 294 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 7 mg · wk 78 · n 465 · Phase 3 · secondary NCT02607865
  • -1.3 vs -1.0 7 mg · wk 52 · n 465 · Phase 3 · secondary NCT02607865
  • -1.2 vs -0.9 7 mg · wk 26 · n 465 · Phase 3 · secondary NCT02607865
  • -2.7 vs -2.2 14 mg · wk 26 · n 130 · Phase 3 · secondary NCT03015220
  • -1.8 vs -0.5 7 mg · wk 26 · n 317 · Phase 3 · secondary NCT04017832
  • -1.1 vs -0.9 3 mg · wk 78 · n 466 · Phase 3 · secondary NCT02607865
  • -1.0 vs -1.0 3 mg · wk 52 · n 466 · Phase 3 · secondary NCT02607865
  • -0.8 vs -0.9 3 mg · wk 26 · n 466 · Phase 3 · secondary NCT02607865
  • -2.2 vs -1.8 14 mg · wk 52 · n 130 · Phase 3 · secondary NCT03015220
  • -2.0 vs -1.8 7 mg · wk 52 · n 132 · Phase 3 · secondary NCT03015220
  • -2.3 vs -2.2 7 mg · wk 26 · n 132 · Phase 3 · secondary NCT03015220
  • -0.9 vs -1.8 3 mg · wk 52 · n 131 · Phase 3 · secondary NCT03015220
  • -1.0 vs -0.5 3 mg · wk 26 · n 322 · Phase 3 · secondary NCT04017832
  • -1.2 vs -2.2 3 mg · wk 26 · n 131 · Phase 3 · secondary NCT03015220
  • -0.3 vs 0.0 wk 104 · n 92 · Phase 3 · secondary NCT02849080
  • -2.4 vs -1.4 wk 52 · n 229 · Phase 3 · secondary NCT02849080

3-point MACE (% with event)

orforglipron
—Not posted · NCT05803421
Semaglutide (Rybelsus)
12% vs 13.8%−1.8 vs placebowk 265 · n 4825NCT03914326
1 other result
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety

Coverage. orforglipron: 14 of 14 rows · Semaglutide (Rybelsus): 13 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricorforglipron
Rows use multiple source trials
Semaglutide (Rybelsus)
Rows use multiple source trials
BMI
absolute change · kg
No placebo or comparator arm
-2.5 kg @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1.9 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-0.7 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.6 kg @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2.9 kg @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-2.5 kg @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
No placebo or comparator arm
-2.13% (n=125) @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-1.97% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.71% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.5% (n=497) @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 5 more doses
-0.4% (n=333) @ 52wk14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-2.1% (n=492) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-1% (n=339) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-1.9% (n=475) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-0.8% (n=345) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7%
responder rate · % of participants
No placebo or comparator arm
90.82% (n=125) @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
86.11% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
82.73% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
39% (n=536) @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
63% (n=535) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
50.5% (n=535) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5
responder rate · % of participants
No placebo or comparator arm
84.56% (n=125) @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
76.23% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
62.64% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
25.8% (n=536) @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
51.2% (n=535) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
39.6% (n=535) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-6 vs -0.5 placebo mmHg @ 40wk36 mga,b,c,d
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more doses
-6.1 vs -0.5 placebo mmHg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-3.2 vs -0.5 placebo mmHg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-4 vs -2 placebo mmHg @ 26wk14 mga,b,c,d
NCT04109547 · Phase 3 · registry result, not featured evidence
show 2 more doses
-2 vs -2 placebo mmHg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
1 vs -2 placebo mmHg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
Waist Circumference Change
absolute change · cm
No placebo or comparator arm
-6.5 cm @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-4.6 cm @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-2.4 cm @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-4 cm @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
-6 cm @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-5 cm @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Weight
percent change · % of baseline
-9.6% vs -2.5% placebo @ 72wkorforglipron 17.2 mge,c,f
NCT05872620 · Phase 3 · sponsor-reported, not registry data
-3.12% (n=93) vs -0.7% (n=97) Sitagliptin @ 104wke,c,f
NCT02849080 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
No placebo or comparator arm
-6.75 kg @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
-5.08 kg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-1.81 kg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-4.4 kg @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
-8.3 kg @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
-7.1 kg @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Weight Loss 10%
responder rate · % of participants
No placebo or comparator arm
37.91% (n=125) @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
24.68% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
10.11% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
13.9% (n=536) @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
37.2% (n=535) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
29% (n=535) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Weight Loss 5%
responder rate · % of participants
No placebo or comparator arm
65.14% (n=125) @ 52wk36 mga,b,c
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more doses
49.52% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
27% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
41% (n=536) @ 52wk14 mg once dailya,b,c
NCT04707469 · Phase 3 · registry result, not featured evidence
show 2 more doses
67.5% (n=535) @ 52wk50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
60% (n=535) @ 52wk25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
Dropout rate
6.7%36 mgg
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
5.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
5.3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3.5%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
8.8%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
6.3%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
7.4%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
11.8%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.7%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
7.8%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
6.5%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
9.4%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
57.1%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
6.9%14 mgg
NCT02906930 · Phase 3
show 39 more results
8%7 mg
NCT02906930 · Phase 3
3.4%3 mg
NCT02906930 · Phase 3
2.7%14 mg
NCT02863328 · Phase 3
5.8%14 mg
NCT02607865 · Phase 3
6.4%7 mg
NCT02607865 · Phase 3
7.1%3 mg
NCT02607865 · Phase 3
2.8%14 mg
NCT02863419 · Phase 3
3.1%14 mg
NCT02827708 · Phase 3
3.3%14 mg
NCT03021187 · Phase 3
4.9%7 mg
NCT03021187 · Phase 3
5.4%3 mg
NCT03021187 · Phase 3
1.5%
NCT03914326 · Phase 3
0.3%
NCT02692716 · Phase 3
11.8%
NCT05035082 · Phase 4 · registry result, not featured evidence
5.4%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
5.6%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.4%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
7.2%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
5%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.6%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
3.1%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
2.1%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
2.3%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.5%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
2.3%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
11.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
11.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
5.7%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
8.6%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2.2%36 mgg
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
4.4%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.5%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
1.4%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
0.7%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.6%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
—3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
—2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
10%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
35.7%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
11.1%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
—14 mgg
NCT02906930 · Phase 3
show 39 more results
—7 mg
NCT02906930 · Phase 3
—3 mg
NCT02906930 · Phase 3
—14 mg
NCT02863328 · Phase 3
—14 mg
NCT02607865 · Phase 3
—7 mg
NCT02607865 · Phase 3
—3 mg
NCT02607865 · Phase 3
—14 mg
NCT02863419 · Phase 3
—14 mg
NCT02827708 · Phase 3
—14 mg
NCT03021187 · Phase 3
—7 mg
NCT03021187 · Phase 3
—3 mg
NCT03021187 · Phase 3
—
NCT03914326 · Phase 3
—
NCT02692716 · Phase 3
—
NCT05035082 · Phase 4 · registry result, not featured evidence
—14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
—14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
—Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
—14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
—2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Serious AEs
4.5%36 mgg
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
2.2%12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
3%3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.8%36 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.1%12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
5.6%3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
3.7%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
2.9%36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
1.8%12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
5.9%3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
3.1%45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
10.6%24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
0%3 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%2 mg
NCT05086445 · Phase 1 · registry result, not featured evidence
0%3/6/12/15 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/12/21/27 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
0%3/6/9/21/36/45 mg QD
NCT04426474 · Phase 1 · registry result, not featured evidence
1.1%14 mgg
NCT02906930 · Phase 3
show 39 more results
1.7%7 mg
NCT02906930 · Phase 3
2.9%3 mg
NCT02906930 · Phase 3
6.6%14 mg
NCT02863328 · Phase 3
9.5%14 mg
NCT02607865 · Phase 3
10.1%7 mg
NCT02607865 · Phase 3
13.7%3 mg
NCT02607865 · Phase 3
10.9%14 mg
NCT02863419 · Phase 3
10.4%14 mg
NCT02827708 · Phase 3
6.6%14 mg
NCT03021187 · Phase 3
10.5%7 mg
NCT03021187 · Phase 3
13.6%3 mg
NCT03021187 · Phase 3
47.9%
NCT03914326 · Phase 3
18.9%
NCT02692716 · Phase 3
10.2%
NCT05035082 · Phase 4 · registry result, not featured evidence
9.9%14 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
8.2%50 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
10.7%25 mg once daily
NCT04707469 · Phase 3 · registry result, not featured evidence
3%14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.1%7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
4.4%3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
3.9%14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
7.7%7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
4.6%3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
9.5%Oral Semaglutide Flex- Main Phase
NCT02849080 · Phase 3 · registry result, not featured evidence
14.2%Oral Semaglutide Flex- Sustainabil
NCT02849080 · Phase 3 · registry result, not featured evidence
9%Oral Semaglutide Flex- Switch
NCT02849080 · Phase 3 · registry result, not featured evidence
0%14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
6.1%7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
4.1%3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
5.4%14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
3%7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
6.9%3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
1.4%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
7.1%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
4.3%40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
2.9%5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
1.4%2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
36 mgg
constipation 29.1%
nausea 27.6%
nasopharyngitis 16.4%
NCT06010004 · Phase 3 · registry result, not featured evidence
show 19 more results
12 mg
constipation 30.4%
nasopharyngitis 22.2%
nausea 19.3%
NCT06010004 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 17.4%
constipation 16.7%
nausea 12.9%
NCT06010004 · Phase 3 · registry result, not featured evidence
36 mg
diarrhoea 25.5% (placebo 9.4%)
diabetic retinopathy 17% (placebo 15.2%)
nausea 17% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
12 mg
diarrhoea 21.2% (placebo 9.4%)
dyspepsia 21.2% (placebo 7.2%)
nausea 19% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
3 mg
diarrhoea 18.9% (placebo 9.4%)
diabetic retinopathy 14.7% (placebo 15.2%)
nausea 12.6% (placebo 2.2%)
NCT05971940 · Phase 3 · registry result, not featured evidence
36 mg
nausea 37% (placebo 5.5%)
vomiting 33.3% (placebo 1.8%)
diarrhoea 25.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
36 mg
nausea 26.5% (placebo 5.5%)
vomiting 20.6% (placebo 1.8%)
eructation 8.8% (placebo 0%)
NCT05048719 · Phase 2 · registry result, not featured evidence
12 mg
nausea 37.5% (placebo 5.5%)
vomiting 21.4% (placebo 1.8%)
diarrhoea 16.1% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 23.5% (placebo 5.5%)
diarrhoea 21.6% (placebo 7.3%)
constipation 13.7% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
vomiting 35.5% (placebo 1.8%)
diarrhoea 29% (placebo 7.3%)
nausea 29% (placebo 5.5%)
NCT05048719 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 28.1% (placebo 7.3%)
nausea 25% (placebo 5.5%)
vomiting 21.9% (placebo 1.8%)
NCT05048719 · Phase 2 · registry result, not featured evidence
24 mg
nausea 34% (placebo 5.5%)
vomiting 27.7% (placebo 1.8%)
diarrhoea 14.9% (placebo 7.3%)
NCT05048719 · Phase 2 · registry result, not featured evidence
3 mg
nausea 55.6% (placebo 25%)
constipation 33.3% (placebo 0%)
vomiting 22.2% (placebo 25%)
NCT05086445 · Phase 1 · registry result, not featured evidence
2 mg
vomiting 40% (placebo 25%)
nausea 30% (placebo 25%)
abdominal distension 20% (placebo 0%)
NCT05086445 · Phase 1 · registry result, not featured evidence
3/6/12/15 mg QD
nausea 50% (placebo 5.9%)
vomiting 50% (placebo 0%)
decreased appetite 40% (placebo 11.8%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21 mg QD
nausea 42.9% (placebo 5.9%)
decreased appetite 28.6% (placebo 11.8%)
covid-19 21.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/12/21/27 mg QD
decreased appetite 55.6% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
nausea 33.3% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9 mg QD
vomiting 55.6% (placebo 0%)
decreased appetite 44.4% (placebo 11.8%)
nausea 44.4% (placebo 5.9%)
NCT04426474 · Phase 1 · registry result, not featured evidence
3/6/9/21/36/45 mg QD
nausea 77.8% (placebo 5.9%)
decreased appetite 66.7% (placebo 11.8%)
vomiting 55.6% (placebo 0%)
NCT04426474 · Phase 1 · registry result, not featured evidence
14 mgg
nausea 16% (placebo 5.6%)
vomiting 6.9% (placebo 2.2%)
decreased appetite 5.1% (placebo 0.6%)
NCT02906930 · Phase 3
show 38 more results
7 mg
nasopharyngitis 6.3% (placebo 3.4%)
headache 5.7% (placebo 5.1%)
diarrhoea 5.1% (placebo 2.2%)
NCT02906930 · Phase 3
3 mg
diarrhoea 8.6% (placebo 2.2%)
nausea 8% (placebo 5.6%)
nasopharyngitis 5.7% (placebo 3.4%)
NCT02906930 · Phase 3
14 mg
nausea 19.8%
diarrhoea 9.3%
vomiting 7.3%
NCT02863328 · Phase 3
14 mg
nausea 15.1%
diarrhoea 12%
nasopharyngitis 10.1%
NCT02607865 · Phase 3
7 mg
nausea 13.4%
diarrhoea 11.4%
nasopharyngitis 10.6%
NCT02607865 · Phase 3
3 mg
nasopharyngitis 11.4%
diarrhoea 9.4%
upper respiratory tract infection 7.7%
NCT02607865 · Phase 3
14 mg
nausea 19.3% (placebo 3.5%)
diarrhoea 15.1% (placebo 7.7%)
nasopharyngitis 14.4% (placebo 10.6%)
NCT02863419 · Phase 3
14 mg
nausea 19% (placebo 7.5%)
constipation 11.7% (placebo 3.7%)
vomiting 11.7% (placebo 1.2%)
NCT02827708 · Phase 3
14 mg
nausea 22.7% (placebo 7.1%)
diarrhoea 14.4% (placebo 6%)
decreased appetite 12.7% (placebo 1.1%)
NCT03021187 · Phase 3
7 mg
nausea 16.6% (placebo 7.1%)
diarrhoea 12.2% (placebo 6%)
nasopharyngitis 11.6% (placebo 14.7%)
NCT03021187 · Phase 3
3 mg
nasopharyngitis 14.7% (placebo 14.7%)
nausea 11.4% (placebo 7.1%)
diarrhoea 8.7% (placebo 6%)
NCT03021187 · Phase 3
diabetic retinopathy 19.5% (placebo 19.3%)
covid-19 15.7% (placebo 16.1%)
nausea 7.1% (placebo 1.3%)
NCT03914326 · Phase 3
covid-19 8.8%
nausea 7.6%
NCT05035082 · Phase 4 · registry result, not featured evidence
14 mg once daily
nausea 18%
diarrhoea 12.4%
covid-19 11.8%
NCT04707469 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 27.3%
vomiting 18.2%
diarrhoea 14.2%
NCT04707469 · Phase 3 · registry result, not featured evidence
25 mg once daily
nausea 27.2%
vomiting 17%
diarrhoea 12.9%
NCT04707469 · Phase 3 · registry result, not featured evidence
14 mg
diarrhoea 13.3%
nausea 12.2%
decreased appetite 9.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
7 mg
nausea 10.9%
diarrhoea 8.9%
decreased appetite 8.4%
NCT04017832 · Phase 3 · registry result, not featured evidence
3 mg
nausea 10%
diarrhoea 8.3%
upper respiratory tract infection 7.2%
NCT04017832 · Phase 3 · registry result, not featured evidence
14 mg
decreased appetite 10.9% (placebo 0%)
diarrhoea 9.3% (placebo 1.5%)
upper respiratory tract infection 7% (placebo 4.6%)
NCT04109547 · Phase 3 · registry result, not featured evidence
7 mg
diarrhoea 9.2% (placebo 1.5%)
upper respiratory tract infection 9.2% (placebo 4.6%)
lipase increased 8.5% (placebo 0%)
NCT04109547 · Phase 3 · registry result, not featured evidence
3 mg
upper respiratory tract infection 8.5% (placebo 4.6%)
lipase increased 5.4% (placebo 0%)
nausea 4.6% (placebo 1.5%)
NCT04109547 · Phase 3 · registry result, not featured evidence
nausea 20.9%
nasopharyngitis 10.3%
headache 9.9%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 22.9%
nasopharyngitis 13.4%
diarrhoea 11.5%
NCT02849080 · Phase 3 · registry result, not featured evidence
nausea 17%
diarrhoea 10%
nasopharyngitis 7%
NCT02849080 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 18.8% (placebo 28.6%)
constipation 12.5% (placebo 6.1%)
decreased appetite 12.5% (placebo 0%)
NCT03018028 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 16.3% (placebo 28.6%)
constipation 12.2% (placebo 6.1%)
nausea 10.2% (placebo 2%)
NCT03018028 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 20.4% (placebo 28.6%)
constipation 10.2% (placebo 6.1%)
periarthritis 10.2% (placebo 4.1%)
NCT03018028 · Phase 3 · registry result, not featured evidence
14 mg
nasopharyngitis 30%
constipation 15.4%
nausea 9.2%
NCT03015220 · Phase 3 · registry result, not featured evidence
7 mg
nasopharyngitis 29.5%
constipation 12.1%
decreased appetite 9.1%
NCT03015220 · Phase 3 · registry result, not featured evidence
3 mg
nasopharyngitis 26%
constipation 9.2%
influenza 6.9%
NCT03015220 · Phase 3 · registry result, not featured evidence
40 mg
nausea 33.8% (placebo 1.4%)
vomiting 19.7% (placebo 4.2%)
decreased appetite 14.1% (placebo 1.4%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 35.7% (placebo 1.4%)
vomiting 22.9% (placebo 4.2%)
diarrhoea 17.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
40 mg
nausea 32.9% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 15.7% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
20 mg
nausea 35.7% (placebo 1.4%)
diarrhoea 20% (placebo 9.9%)
vomiting 17.1% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
10 mg
nausea 33.3% (placebo 1.4%)
diarrhoea 23.2% (placebo 9.9%)
vomiting 20.3% (placebo 4.2%)
NCT01923181 · Phase 2 · registry result, not featured evidence
5 mg
nausea 14.3% (placebo 1.4%)
headache 12.9% (placebo 5.6%)
diarrhoea 10% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence
2.5 mg
nausea 12.9% (placebo 1.4%)
nasopharyngitis 8.6% (placebo 12.7%)
diarrhoea 7.1% (placebo 9.9%)
NCT01923181 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 40 weeks versus 26 weeks.
  5. ePopulation context differs: registered conditions differ.
  6. fAssessment timepoints differ: 72 weeks versus 104 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

orforglipron

HbA1c Less Than 5 7 30.51% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
21.92% (n=128) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
7.7% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL -64.5 mg @ 52wk36 mg
absolute change · mg
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-55.1 mg @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-51.7 mg @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
Weight Loss 15% 20.94% (n=125) @ 52wk36 mg
responder rate · % of participants
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
13.96% (n=127) @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
2.79% (n=125) @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -82.27 mg/dL @ 52wk36 mg
absolute change · mg/dL
No placebo or comparator arm
NCT06010004 · Phase 3 · registry result, not featured evidence
show 2 more results
-73.14 mg/dL @ 52wk12 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
-66.32 mg/dL @ 52wk3 mg
NCT06010004 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 78.99% (n=119) vs 37.11% (n=97) placebo @ 40wk36 mg
responder rate · % of participants
NCT05971940 · Phase 3 · registry result, not featured evidence
show 7 more results
92.75% (n=57) vs 24.27% (n=55) placebo @ 26wk36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
81.25% (n=112) vs 37.11% (n=97) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
78.92% (n=49) vs 24.27% (n=55) placebo @ 26wk12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
78.15% (n=119) vs 37.11% (n=97) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
65.17% (n=46) vs 24.27% (n=55) placebo @ 26wk3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
95.76% (n=58) vs 24.27% (n=55) placebo @ 26wk45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
91.24% (n=42) vs 24.27% (n=55) placebo @ 26wk24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
HbA1c Less Than or Equal to 6.5 68.91% (n=119) vs 18.56% (n=97) placebo @ 40wk36 mg
responder rate · % of participants
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
68.75% (n=112) vs 18.56% (n=97) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
66.39% (n=119) vs 18.56% (n=97) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Fasting Serum Glucose Change mg/dL -37.8 vs -1.1 placebo mg @ 40wk36 mg
absolute change · mg
NCT05971940 · Phase 3 · registry result, not featured evidence
show 7 more results
-53.9 vs -11.1 placebo mg @ 26wk36 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-37.4 vs -1.1 placebo mg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-53.7 vs -11.1 placebo mg @ 26wk12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-30.6 vs -1.1 placebo mg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-32.6 vs -11.1 placebo mg @ 26wk3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-55.9 vs -11.1 placebo mg @ 26wk45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
-52.2 vs -11.1 placebo mg @ 26wk24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
Non-HDL-C -7.91% (n=137) vs 3.19% (n=135) placebo @ 40wk36 mg
percent change · % of baseline
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-4.8% (n=131) vs 3.19% (n=135) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-1.82% (n=136) vs 3.19% (n=135) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Triglycerides -14% (n=136) vs 0% (n=135) placebo @ 40wk36 mg
percent change · % of baseline
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-16.5% (n=130) vs 0% (n=135) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-9.1% (n=136) vs 0% (n=135) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
SMBG Daily Average Change mg/dL -58.1 vs -17.6 placebo mg @ 40wk36 mg
absolute change · mg
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
-56 vs -17.6 placebo mg @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
-43.6 vs -17.6 placebo mg @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
Weight Loss 5% 66.39% (n=119) vs 14.58% (n=96) placebo @ 40wk36 mg
responder rate · % of participants
NCT05971940 · Phase 3 · registry result, not featured evidence
show 2 more results
58.56% (n=111) vs 14.58% (n=96) placebo @ 40wk12 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
47.06% (n=119) vs 14.58% (n=96) placebo @ 40wk3 mg
NCT05971940 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 6 5 79.39% (n=57) vs 14.56% (n=22) placebo @ 26wk36 mg
responder rate · % of participants
NCT05048719 · Phase 2 · registry result, not featured evidence
show 4 more results
70.73% (n=49) vs 14.56% (n=22) placebo @ 26wk12 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
45.3% (n=46) vs 14.56% (n=22) placebo @ 26wk3 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
83.52% (n=58) vs 14.56% (n=22) placebo @ 26wk45 mg
NCT05048719 · Phase 2 · registry result, not featured evidence
80.12% (n=42) vs 14.56% (n=22) placebo @ 26wk24 mg
NCT05048719 · Phase 2 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

Semaglutide (Rybelsus)

HbA1c -1.5% (n=175) vs -0.3% (n=178) placebo @ 26wk14 mg
absolute change · percentage points
In-trial
NCT02906930 · Phase 3
show 11 more results
-1.3% (n=411) vs -0.9% (n=410) Empagliflozin 25 mg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-1.3% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-1.2% (n=285) vs -0.1% (n=142) placebo @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-1.1% (n=163) vs -0.2% (n=161) placebo @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-1.3% (n=181) vs -0.1% (n=184) placebo @ 26wk14 mg
In-trial
NCT03021187 · Phase 3
-1.3% (n=175) vs -0.3% (n=178) placebo @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-1.1% (n=465) vs -0.8% (n=467) Sitagliptin @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1% (n=182) vs -0.1% (n=184) placebo @ 26wk7 mg
In-trial
NCT03021187 · Phase 3
-0.9% (n=175) vs -0.3% (n=178) placebo @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-0.6% (n=466) vs -0.8% (n=467) Sitagliptin @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-0.5% (n=184) vs -0.1% (n=184) placebo @ 26wk3 mg
In-trial
NCT03021187 · Phase 3
Weight -4 vs -1.4 placebo kg @ 26wk14 mg
absolute change · kg
In-trial
NCT02906930 · Phase 3
show 9 more results
-3.9 vs -3.8 Empagliflozin 25 mg kg @ 26wk14 mg
In-trial
NCT02863328 · Phase 3
-3.1 vs -0.6 Sitagliptin kg @ 26wk14 mg
In-trial
NCT02607865 · Phase 3
-4.4 vs -0.6 placebo kg @ 26wk14 mg
In-trial
NCT02863419 · Phase 3
-3.5 vs -0.9 placebo kg @ 26wk14 mg
In-trial
NCT02827708 · Phase 3
-2.6 vs -1.4 placebo kg @ 26wk7 mg
In-trial
NCT02906930 · Phase 3
-2.2 vs -0.6 Sitagliptin kg @ 26wk7 mg
In-trial
NCT02607865 · Phase 3
-1.5 vs -1.4 placebo kg @ 26wk3 mg
In-trial
NCT02906930 · Phase 3
-1.2 vs -0.6 Sitagliptin kg @ 26wk3 mg
In-trial
NCT02607865 · Phase 3
-2.7 vs -0.7 Sitagliptin kg @ 52wk
In-trial
NCT02849080 · Phase 3 · registry result, not featured evidence
SMBG 7-point -2.3 vs -0.5 placebo mmol/L @ 26wk14 mg
absolute change · mmol/L
NCT02906930 · Phase 3
show 36 more results
-2.3 vs -1.9 Empagliflozin 25 mg mmol/L @ 26wk14 mg
NCT02863328 · Phase 3
-2.3 vs -2.1 Empagliflozin 25 mg mmol/L @ 52wk14 mg
NCT02863328 · Phase 3
-1.7 vs -1.2 Sitagliptin mmol/L @ 26wk14 mg
NCT02607865 · Phase 3
-1.8 vs -1.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-1.7 vs -1.3 Sitagliptin mmol/L @ 78wk14 mg
NCT02607865 · Phase 3
-2.2 vs -0.7 placebo mmol/L @ 26wk14 mg
NCT02863419 · Phase 3
-2.2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-2 vs -0.3 placebo mmol/L @ 26wk14 mg
NCT03021187 · Phase 3
-2 vs -0.9 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-2.6 vs -1.2 Sitagliptin mmol/L @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-3.1 vs -0.8 placebo mmol/L @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.1 vs 0 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-3.5 vs -2.9 Dulaglutide mmol/L @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-3.3 vs -2.6 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.1 vs -0.5 placebo mmol/L @ 26wk7 mg
NCT02906930 · Phase 3
-1.5 vs -1.2 Sitagliptin mmol/L @ 26wk7 mg
NCT02607865 · Phase 3
-1.5 vs -1.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-1.5 vs -1.3 Sitagliptin mmol/L @ 78wk7 mg
NCT02607865 · Phase 3
-1.8 vs -0.3 placebo mmol/L @ 26wk7 mg
NCT03021187 · Phase 3
-1.7 vs -0.9 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-2.3 vs -1.2 Sitagliptin mmol/L @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.6 vs -0.8 placebo mmol/L @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.2 vs 0 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.7 vs -2.9 Dulaglutide mmol/L @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.5 vs -2.6 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.8 vs -0.5 placebo mmol/L @ 26wk3 mg
NCT02906930 · Phase 3
-1.1 vs -1.2 Sitagliptin mmol/L @ 26wk3 mg
NCT02607865 · Phase 3
-1.3 vs -1.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-1.3 vs -1.3 Sitagliptin mmol/L @ 78wk3 mg
NCT02607865 · Phase 3
-1.2 vs -0.3 placebo mmol/L @ 26wk3 mg
NCT03021187 · Phase 3
-1.6 vs -0.9 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-1.5 vs -1.2 Sitagliptin mmol/L @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.2 vs -0.8 placebo mmol/L @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.7 vs 0 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.8 vs -2.9 Dulaglutide mmol/L @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.7 vs -2.6 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
PPG Excursion -1.2 vs -0.3 placebo mmol/L @ 26wk14 mg
absolute change · mmol/L
NCT02906930 · Phase 3
show 36 more results
-0.5 vs -0.4 Empagliflozin 25 mg mmol/L @ 26wk14 mg
NCT02863328 · Phase 3
-0.6 vs -0.4 Empagliflozin 25 mg mmol/L @ 52wk14 mg
NCT02863328 · Phase 3
-0.6 vs -0.6 Sitagliptin mmol/L @ 26wk14 mg
NCT02607865 · Phase 3
-0.7 vs -0.4 Sitagliptin mmol/L @ 52wk14 mg
NCT02607865 · Phase 3
-0.6 vs -0.6 Sitagliptin mmol/L @ 78wk14 mg
NCT02607865 · Phase 3
-0.7 vs -0.2 placebo mmol/L @ 26wk14 mg
NCT02863419 · Phase 3
-0.5 vs -0.4 placebo mmol/L @ 52wk14 mg
NCT02863419 · Phase 3
-1.2 vs -0.1 placebo mmol/L @ 26wk14 mg
NCT03021187 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk14 mg
NCT03021187 · Phase 3
-1 vs -0.6 Sitagliptin mmol/L @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2 vs -0.5 placebo mmol/L @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2 vs -0.1 placebo mmol/L @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.7 Dulaglutide mmol/L @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.7 Dulaglutide mmol/L @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.3 placebo mmol/L @ 26wk7 mg
NCT02906930 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 26wk7 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk7 mg
NCT02607865 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 78wk7 mg
NCT02607865 · Phase 3
-0.8 vs -0.1 placebo mmol/L @ 26wk7 mg
NCT03021187 · Phase 3
-0.7 vs -0.3 placebo mmol/L @ 52wk7 mg
NCT03021187 · Phase 3
-0.9 vs -0.6 Sitagliptin mmol/L @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-1.2 vs -0.5 placebo mmol/L @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.1 placebo mmol/L @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.3 vs -0.7 Dulaglutide mmol/L @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.7 Dulaglutide mmol/L @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.3 placebo mmol/L @ 26wk3 mg
NCT02906930 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 26wk3 mg
NCT02607865 · Phase 3
-0.4 vs -0.4 Sitagliptin mmol/L @ 52wk3 mg
NCT02607865 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 78wk3 mg
NCT02607865 · Phase 3
-0.3 vs -0.1 placebo mmol/L @ 26wk3 mg
NCT03021187 · Phase 3
-0.3 vs -0.3 placebo mmol/L @ 52wk3 mg
NCT03021187 · Phase 3
-0.4 vs -0.6 Sitagliptin mmol/L @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.7 vs -0.5 placebo mmol/L @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.5 vs -0.1 placebo mmol/L @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.7 Dulaglutide mmol/L @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.7 Dulaglutide mmol/L @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
BMI -1.5 vs -0.5 placebo kg @ 26wk14 mg
absolute change · kg
NCT02906930 · Phase 3
show 49 more results
-1.4 vs -1.4 Empagliflozin 25 mg kg @ 26wk14 mg
NCT02863328 · Phase 3
-1.5 vs -1.4 Empagliflozin 25 mg kg @ 52wk14 mg
NCT02863328 · Phase 3
-1.1 vs -0.2 Sitagliptin kg @ 26wk14 mg
NCT02607865 · Phase 3
-1.2 vs -0.3 Sitagliptin kg @ 52wk14 mg
NCT02607865 · Phase 3
-1.1 vs -0.4 Sitagliptin kg @ 78wk14 mg
NCT02607865 · Phase 3
-1.6 vs -0.2 placebo kg @ 26wk14 mg
NCT02863419 · Phase 3
-1.6 vs -0.4 placebo kg @ 52wk14 mg
NCT02863419 · Phase 3
-1.2 vs -0.3 placebo kg @ 26wk14 mg
NCT02827708 · Phase 3
-1.4 vs -0.2 placebo kg @ 26wk14 mg
NCT03021187 · Phase 3
-1.4 vs 0.2 placebo kg @ 52wk14 mg
NCT03021187 · Phase 3
-1.4 vs -0.2 Sitagliptin kg @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.4 placebo kg @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.4 placebo kg @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.1 vs -0.4 placebo kg @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.8 vs 0.1 Dulaglutide kg @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs 0.3 Dulaglutide kg @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.5 placebo kg @ 26wk7 mg
NCT02906930 · Phase 3
-0.8 vs -0.2 Sitagliptin kg @ 26wk7 mg
NCT02607865 · Phase 3
-0.9 vs -0.3 Sitagliptin kg @ 52wk7 mg
NCT02607865 · Phase 3
-1 vs -0.4 Sitagliptin kg @ 78wk7 mg
NCT02607865 · Phase 3
-1 vs -0.2 placebo kg @ 26wk7 mg
NCT03021187 · Phase 3
-0.8 vs 0.2 placebo kg @ 52wk7 mg
NCT03021187 · Phase 3
-1.1 vs -0.2 Sitagliptin kg @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.8 vs -0.4 placebo kg @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.4 placebo kg @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.4 placebo kg @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.4 vs 0.1 Dulaglutide kg @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.3 vs 0.3 Dulaglutide kg @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.5 placebo kg @ 26wk3 mg
NCT02906930 · Phase 3
-0.4 vs -0.2 Sitagliptin kg @ 26wk3 mg
NCT02607865 · Phase 3
-0.6 vs -0.3 Sitagliptin kg @ 52wk3 mg
NCT02607865 · Phase 3
-0.7 vs -0.4 Sitagliptin kg @ 78wk3 mg
NCT02607865 · Phase 3
-0.5 vs -0.2 placebo kg @ 26wk3 mg
NCT03021187 · Phase 3
-0.3 vs 0.2 placebo kg @ 52wk3 mg
NCT03021187 · Phase 3
-0.5 vs -0.2 Sitagliptin kg @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-0.4 vs -0.4 placebo kg @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.1 vs -0.4 placebo kg @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0 vs -0.4 placebo kg @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.1 vs 0.1 Dulaglutide kg @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
0 vs 0.3 Dulaglutide kg @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.37 vs -0.43 placebo kg @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.04 vs -0.43 placebo kg @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.92 vs -0.43 placebo kg @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-1.93 vs -0.43 placebo kg @ 26wk20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-1.72 vs -0.43 placebo kg @ 26wk10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-0.98 vs -0.43 placebo kg @ 26wk5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-0.67 vs -0.43 placebo kg @ 26wk2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-1 vs -0.3 Sitagliptin kg @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-0.9 vs -0.3 Sitagliptin kg @ 104wk
NCT02849080 · Phase 3 · registry result, not featured evidence
Waist Circumference Change -4.1 vs -0.9 placebo cm @ 26wk14 mg
absolute change · cm
NCT02906930 · Phase 3
show 49 more results
-3.9 vs -2.9 Empagliflozin 25 mg cm @ 26wk14 mg
NCT02863328 · Phase 3
-3.7 vs -2.9 Empagliflozin 25 mg cm @ 52wk14 mg
NCT02863328 · Phase 3
-2.3 vs -0.6 Sitagliptin cm @ 26wk14 mg
NCT02607865 · Phase 3
-2.6 vs -0.5 Sitagliptin cm @ 52wk14 mg
NCT02607865 · Phase 3
-2.4 vs -0.7 Sitagliptin cm @ 78wk14 mg
NCT02607865 · Phase 3
-4.2 vs -1.2 placebo cm @ 26wk14 mg
NCT02863419 · Phase 3
-4.4 vs -1.7 placebo cm @ 52wk14 mg
NCT02863419 · Phase 3
-2.8 vs -0.7 placebo cm @ 26wk14 mg
NCT02827708 · Phase 3
-3.6 vs -0.6 placebo cm @ 26wk14 mg
NCT03021187 · Phase 3
-4 vs 0.3 placebo cm @ 52wk14 mg
NCT03021187 · Phase 3
-3.7 vs -0.8 Sitagliptin cm @ 26wk14 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.8 vs -1.4 placebo cm @ 26wk14 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-1.3 vs -0.5 placebo cm @ 26wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-2.7 vs -0.9 placebo cm @ 52wk14 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1.2 vs 0.3 Dulaglutide cm @ 26wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-1.7 vs 0.7 Dulaglutide cm @ 52wk14 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2.3 vs -0.9 placebo cm @ 26wk7 mg
NCT02906930 · Phase 3
-1.8 vs -0.6 Sitagliptin cm @ 26wk7 mg
NCT02607865 · Phase 3
-2.3 vs -0.5 Sitagliptin cm @ 52wk7 mg
NCT02607865 · Phase 3
-2.4 vs -0.7 Sitagliptin cm @ 78wk7 mg
NCT02607865 · Phase 3
-2.3 vs -0.6 placebo cm @ 26wk7 mg
NCT03021187 · Phase 3
-2.3 vs 0.3 placebo cm @ 52wk7 mg
NCT03021187 · Phase 3
-2.7 vs -0.8 Sitagliptin cm @ 26wk7 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.2 vs -1.4 placebo cm @ 26wk7 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
-0.6 vs -0.5 placebo cm @ 26wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-1 vs -0.9 placebo cm @ 52wk7 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
-0.6 vs 0.3 Dulaglutide cm @ 26wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.8 vs 0.7 Dulaglutide cm @ 52wk7 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-2 vs -0.9 placebo cm @ 26wk3 mg
NCT02906930 · Phase 3
-0.7 vs -0.6 Sitagliptin cm @ 26wk3 mg
NCT02607865 · Phase 3
-1.3 vs -0.5 Sitagliptin cm @ 52wk3 mg
NCT02607865 · Phase 3
-1.2 vs -0.7 Sitagliptin cm @ 78wk3 mg
NCT02607865 · Phase 3
-0.9 vs -0.6 placebo cm @ 26wk3 mg
NCT03021187 · Phase 3
-0.8 vs 0.3 placebo cm @ 52wk3 mg
NCT03021187 · Phase 3
-1.6 vs -0.8 Sitagliptin cm @ 26wk3 mg
NCT04017832 · Phase 3 · registry result, not featured evidence
-2.1 vs -1.4 placebo cm @ 26wk3 mg
NCT04109547 · Phase 3 · registry result, not featured evidence
0.5 vs -0.5 placebo cm @ 26wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0.2 vs -0.9 placebo cm @ 52wk3 mg
NCT03018028 · Phase 3 · registry result, not featured evidence
0 vs 0.3 Dulaglutide cm @ 26wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-0.1 vs 0.7 Dulaglutide cm @ 52wk3 mg
NCT03015220 · Phase 3 · registry result, not featured evidence
-5.71 vs -2.29 placebo cm @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-4.86 vs -2.29 placebo cm @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-6.24 vs -2.29 placebo cm @ 26wk40 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-4.08 vs -2.29 placebo cm @ 26wk20 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-5.28 vs -2.29 placebo cm @ 26wk10 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.29 vs -2.29 placebo cm @ 26wk5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2 vs -2.29 placebo cm @ 26wk2.5 mg
NCT01923181 · Phase 2 · registry result, not featured evidence
-2.6 vs -0.7 Sitagliptin cm @ 52wk
NCT02849080 · Phase 3 · registry result, not featured evidence
-1.8 vs -0.9 Sitagliptin cm @ 104wk
NCT02849080 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 7% 76.9% (n=160) vs 31% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 123 Participants as posted
show 10 more results
57.8% (n=154) vs 22.6% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 89 Participants as posted
75.8% (n=298) vs 36.5% (n=334) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 226 Participants as posted
79.3% (n=116) vs 25.5% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 92 Participants as posted
68.8% (n=160) vs 31% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 110 Participants as posted
67.6% (n=315) vs 36.5% (n=334) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 213 Participants as posted
85.5% (n=117) vs 25.5% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 100 Participants as posted
55.1% (n=167) vs 31% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 92 Participants as posted
43.3% (n=321) vs 36.5% (n=334) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 139 Participants as posted
65.8% (n=114) vs 25.5% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 75 Participants as posted
58.3% (n=326) vs 45.4% (n=293) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 190 Participants as posted
HbA1c 6.5 or Less 63.8% (n=160) vs 17.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 102 Participants as posted
show 2 more results
47.5% (n=160) vs 17.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 76 Participants as posted
35.9% (n=167) vs 17.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 60 Participants as posted
Weight Loss 5% 41.3% (n=160) vs 14.9% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 66 Participants as posted
show 11 more results
35.7% (n=154) vs 9.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 55 Participants as posted
44.7% (n=333) vs 8% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
37.1% (n=116) vs 10.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
26.9% (n=160) vs 14.9% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 43 Participants as posted
31.3% (n=342) vs 8% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
24.4% (n=119) vs 10.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
19.6% (n=168) vs 14.9% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 33 Participants as posted
16% (n=343) vs 8% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
14.8% (n=115) vs 10.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 17 Participants as posted
36.9% (n=298) vs 31.9% (n=260) Other Oral Glucose-lowering Medication @ 52wk*
Yes
NCT05035082 · Phase 4 · registry result, not featured evidence · converted to % from 110 Participants as posted
27% (n=233) vs 12.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 63 Participants as posted
Weight Loss 10% 14.4% (n=160) vs 1.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 23 Participants as posted
show 10 more results
8.4% (n=154) vs 0% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 13 Participants as posted
12.6% (n=333) vs 0.6% (n=351) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 42 Participants as posted
10.3% (n=116) vs 0% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 12 Participants as posted
8.1% (n=160) vs 1.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 13 Participants as posted
7% (n=342) vs 0.6% (n=351) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 24 Participants as posted
5.9% (n=119) vs 0% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 7 Participants as posted
2.4% (n=168) vs 1.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 4 Participants as posted
1.5% (n=343) vs 0.6% (n=351) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
4.3% (n=115) vs 0% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 5 Participants as posted
6.4% (n=233) vs 2.1% (n=239) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 15 Participants as posted
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain 68.8% (n=160) vs 23.2% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 110 Participants as posted
show 10 more results
50.6% (n=154) vs 17.4% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 78 Participants as posted
66.9% (n=332) vs 22.6% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 222 Participants as posted
72.4% (n=116) vs 17.9% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 84 Participants as posted
56.9% (n=160) vs 23.2% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 91 Participants as posted
57.5% (n=339) vs 22.6% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 195 Participants as posted
68.4% (n=117) vs 17.9% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted
37.1% (n=167) vs 23.2% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 62 Participants as posted
33.1% (n=344) vs 22.6% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 114 Participants as posted
47.4% (n=114) vs 17.9% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 54 Participants as posted
45.2% (n=230) vs 14.7% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 104 Participants as posted
HbA1c Reduction 1% and Weight Loss 3% 50.6% (n=160) vs 10.7% (n=168) placebo @ 26wk14 mg
event count · % of participants
NCT02906930 · Phase 3 · converted to % from 81 Participants as posted
show 10 more results
39% (n=154) vs 7.7% (n=155) placebo @ 26wk*14 mg
Yes
NCT02827708 · Phase 3 · converted to % from 60 Participants as posted
47.9% (n=332) vs 9.4% (n=350) Sitagliptin @ 26wk*14 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 159 Participants as posted
45.7% (n=116) vs 9.4% (n=106) placebo @ 26wk*14 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 53 Participants as posted
36.9% (n=160) vs 10.7% (n=168) placebo @ 26wk*7 mg
Yes
NCT02906930 · Phase 3 · converted to % from 59 Participants as posted
37.8% (n=339) vs 9.4% (n=350) Sitagliptin @ 26wk*7 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 128 Participants as posted
36.8% (n=117) vs 9.4% (n=106) placebo @ 26wk*7 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 43 Participants as posted
18% (n=167) vs 10.7% (n=168) placebo @ 26wk*3 mg
Yes
NCT02906930 · Phase 3 · converted to % from 30 Participants as posted
18.6% (n=344) vs 9.4% (n=350) Sitagliptin @ 26wk*3 mg
Yes
NCT04017832 · Phase 3 · registry result, not featured evidence · converted to % from 64 Participants as posted
22.8% (n=114) vs 9.4% (n=106) placebo @ 26wk*3 mg
Yes
NCT04109547 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
34.8% (n=230) vs 10.5% (n=238) Sitagliptin @ 52wk*
Yes
NCT02849080 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted

+ 115 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: orforglipron's landscape · Semaglutide (Rybelsus)'s landscape